CoChat

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

Clendening, James W., Pandyra, Aleksandra, Li, Zhihua, Boutros, Paul C., Martirosyan, Anna, Lehner, Richard, Jurisica, Igor, Trudel, Suzanne, Penn, Linda Z. · 2010 · Blood
Cited by 100

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Statin inhibitors, used to control hypercholesterolemia, trigger apoptosis of hematologic tumor cells and therefore have immediate potential as anticancer agents. Evaluations of statins in acute myelogenous leukemia and multiple myeloma have shown that statin efficacy is mixed, with only a subset of tumor cells being highly responsive. Our goal was to distinguish molecular features of statin-sensitive and -insensitive myeloma cells and gain insight into potential predictive markers. We show that dysregulation of the mevalonate pathway is a key determinant of sensitivity to statin-induced apoptosis in multiple myeloma. In sensitive cells, the classic feedback response to statin exposure is lost. This results in deficient up-regulation of 2 isoforms of hydroxymethylglutaryl coenzyme A reductase: the rate-limiting enzyme of the mevalonate pathway and hydroxymethylglutaryl coenzyme A synthase 1. To ascertain the clinical utility of these findings, we demonstrate that a subset of primary myeloma cells is sensitive to statins and that monitoring dysregulation of the mevalonate pathway may distinguish these cancers. We also show statins are highly effective and well tolerated in an orthotopic model of myeloma using cells harboring this dysregulation. This determinant of sensitivity further provides molecular rationale for the significant therapeutic index of statins on these tumor cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-07-230508

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 100

Metadata

Authors
Clendening, J. W., Pandyra, A., Li, Z., Boutros, P. C., Martirosyan, A., Lehner, R., Jurisica, I., Trudel, S., & Penn, L. Z.
Venue
Blood
Published
2010-06-10
Volume
115
Issue
23
Pages
4787-4797
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2035401368
Cited by
100
References
3
FWCI
1.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2009-07-230508
The paper
Clendening, J. W., Pandyra, A., Li, Z., Boutros, P. C., Martirosyan, A., Lehner, R., Jurisica, I., Trudel, S., & Penn, L. Z. (2010). Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood. https://doi.org/10.1182/blood-2009-07-230508

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.